Cryogenic electron microscopy-based understanding of viral vector heterogeneity to aide process development

基于低温电子显微镜的病毒载体异质性理解有助于工艺开发

• 批准号: 2879798
• 金额: --
• 依托单位: University College London
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-2879798
• 关键词: Cryogenic; electron; microscopy; based; understanding

Viral vectors can be used as oncolytic viruses, gene-based vaccines, and gene therapy vectors. However, as highlighted by the adverse reactions observed with the recent ChAdOx1 nCoV-19 vaccine and gene therapy trials, gaps remain in our understanding of these products. This currently limits our ability to engineer the virus's tropism, immunogenicity and manufacturability. We seek to address the quality of virus particle synthesis and improve the proportion of mature virus particles in the product. This will be achieved by harnessing the power of computation at multiscale resolution to capture new insights into the biological assembly and disassembly pathways of the viral capsid, centering on the role of the portal protein, towards 'computational microscopy' of viral infectivity.Using adenovirus (Ad5) as our model system we have demonstrated that cryo-EM analysis can identify particle surface morphologies, e.g. fiber molecules and is a technique that could be applied to identify key quality markers on a range of viral vector-like biotherapeutics. Gathering larger cryo-electron microscopy datasets via this project will allow us to probe key structural features critical to viral infectivity, including the portal structure in the capsid and the spike proteins. Key to this is our ability to implement atomic level simulations in collaboration with the Rouse lab (the secondary supervisor) and create samples where changes to the processing conditions can be used to create samples with known changes to viral heterogeneity. Once optimised, these novel methods will be expanded to analyse lentiviral (LV) and adeno-associated virus (AAV) vector systems to fully complement the predominant platforms being applied to gene delivery.

病毒载体可用作溶瘤病毒、基因疫苗和基因治疗载体。然而，正如最近 ChAdOx1 nCoV-19 疫苗和基因治疗试验中观察到的不良反应所强调的那样，我们对这些产品的理解仍然存在差距。目前这限制了我们设计病毒的趋向性、免疫原性和可制造性的能力。我们致力于解决病毒颗粒合成的质量问题，提高产品中成熟病毒颗粒的比例。这将通过利用多尺度分辨率的计算能力来捕获对病毒衣壳的生物组装和拆卸途径的新见解，以门户蛋白的作用为中心，实现病毒感染性的“计算显微镜”。 Ad5）作为我们的模型系统，我们已经证明冷冻电镜分析可以识别颗粒表面形态，例如颗粒表面形态。纤维分子，是一种可用于识别一系列病毒载体样生物治疗药物的关键质量标记的技术。通过该项目收集更大的冷冻电子显微镜数据集将使我们能够探测对病毒感染性至关重要的关键结构特征，包括衣壳中的门户结构和刺突蛋白。关键是我们能够与 Rouse 实验室（二级主管）合作实施原子级模拟，并创建样本，其中处理条件的变化可用于创建已知病毒异质性变化的样本。一旦优化，这些新方法将扩展到分析慢病毒（LV）和腺相关病毒（AAV）载体系统，以充分补充应用于基因传递的主要平台。